Navigation Links
Global Network for Neglected Tropical Diseases Partners with IDB, PAHO to Control and Eliminate Neglected Tropical Diseases in Latin America, Caribbean
Date:9/8/2009

and eliminate NTDs, the most common infections of more than 200 million of the poorest people in the Latin American and Caribbean region. They include tens of millions of cases of intestinal worm infections, such as whipworm, large common roundworm, and hookworm, and almost 10 million cases of Chagas disease, as well as schistosomiasis, trachoma, dengue fever, leishmaniasis, lymphatic filariasis (LF), and onchocerciasis.

NTDs produce extreme poverty through their impact on children's physical and cognitive development, pregnancy outcome and worker productivity. However, with a firm commitment from the public and private sectors, it is possible to eliminate onchocerciasis, lymphatic filariasis and trachoma throughout the region as well as schistosomiasis in the Caribbean.

Ultimately, the roadmap for the control and elimination of the more widespread NTDs will require an inter-sectoral approach that bridges public health, social services, and environmental interventions. The IDB has been a leader in championing this approach through its efforts to create new linkages between water and sanitation projects and public health programs.

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2844964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Global Financial Crisis a Key Driver in Market Conditions for Property, Casualty, and Directors and Officers Lines, Says Aon
2. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
3. SYGNIS to Present at the 11th Rodman & Renshaw Annual Global Investment Conference
4. Reportlinker Adds Liver Disease Treatments: The Global Market Report
5. Reportlinker Adds Anti-aging Products and Services: The Global Market Report
6. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
7. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
8. Reportlinker Adds Biologic Imaging Reagents: Technologies and Global Markets Report
9. ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference
10. Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference
11. Hologic to Present at the 2009 Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... ROCHESTER, Minn. Positively charged gold nanoparticles are ... manage to avoid nanoparticle toxicity. Mayo Clinic researchers ... the nanoparticles effective against ovarian cancer cells. The ... of the Journal of Biological Chemistry ., ... ovarian cancer cells by preventing the cell death ...
(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 TheBeautyPlace.com helps ... day. TheBeautyPlace.com features a Big Day Kit including all ... might need to shine on their Wedding Day. , ... to smile about on their Wedding Day. Flowers blooming ... the start of wedding season. From Memorial Day to ...
(Date:5/21/2013)... St. Louis, MO (PRWEB) May 21, 2013 ... the first insulin pump she used with her patients in the ... the “big blue brick.” For the most part, it could only ... greatly in the 30 years since then, and the advantages are ... device worn on the outside of the body, often on a ...
(Date:5/21/2013)... The producers of Net Worth Business TV ... Ontario, Canada. The area is famous for its natural beauty ... It is located an hour from Toronto and is easily ... the Kawartha Hills, home to several towns, villages and hamlets ... area. Residents and visitors to this region will be able ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:Net Worth Business TV Announces May Air Dates for Peterborough, Ontario 2
... Society, the largest non-government, not-for-profit funding source of cancer research ... training grants totaling more than $52.6 million in the first ... are new and 18 are renewals of previous grants. All ... The American Cancer Societys Research and Training Program has funded ...
... III development of ,GI-friendly, NSAIDs for mild ... Horizon Therapeutics, Inc. is pleased to announce that ... showcase Horizon,s ... including its recent completion of Series C financing, and ...
... Calcium Brand Enriches Consumer Care Division,s Key ... Nutritionals Product Portfolio, ... that its Consumer Care Division has received regulatory,approvals necessary to ... United States. The U.S. portion of the,transaction with Mission Pharmacal ...
... Oct. 5 Eli Lilly and Company,announced today ... the U.S. Food,and Drug Administration (FDA), the company ... fluoxetine HCl) U.S. product,labels. This new labeling information ... . The updates reflect recently completed pooled ...
... (CTI),(Nasdaq: CTIC ; MTAX) management will present at ... The conference will be held October 9-11, 2007, at ... Wednesday, October 10 at 12:45 p.m.,(PT). The conference will ... the presentation. The webcast can be accessed at, http://www.cticseattle.com ...
... SAN FRANCISCO, Calif., Oct. 5 Anesiva,Inc. (Nasdaq: ... company,s,chief executive officer, will present at the Biotechnology Industry,Organization,s ... am PDT in San Francisco. To access the ... http://www.anesiva.com and go to the Investors page, ...
Cached Medicine News:Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 3Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 2Health News:Bayer HealthCare Cleared to Acquire Citracal(R) 3Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 2Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 3Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 4Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 5Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 6Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 7Health News:Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels 8
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will ... Conference on Monday, September 20, 2010.  The presentation is ... be accessed through the Company,s web site, www.regeneron.com ... of the presentation will be available after the live ...
... Shield Healthcare, a leading provider of medical supplies for ... annual story contest on "What Makes Caregiving Rewarding?" designed ... home healthcare  professionals, featuring celebrity contest judge, Sandra Mitchell ... caregiving is a demanding job. A significant number of ...
Cached Medicine Technology:Shield Healthcare Announces 10th Annual Caregiver Story Contest 2
The ImmunoWELL TPO IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroid peroxidase (microsome) in serum and is used as ...
... The ImmunoDOT Autoimmunity Screening Panel 4 ... for screening and detection of autoantibodies ... (SS-A, SS-B, RNP/Sm, and Sm) in ... aid in the diagnosis of systemic ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
Rad-5 signal extraction pulse oximeter™...
Medicine Products: